If AI Healthcare is the next breakout, read these 3 stocks

Artificial intelligence in healthcare sits at the crossroads of a world focused on powerful data, rising healthcare costs, inflation, energy shocks, and supply chain changes. While oil, interest rates, and trade headlines are pulling the market in different directions, AI tools that can improve the accuracy, access, and affordability of healthcare are getting a lot of attention. The Transformative AI Healthcare Stocks screen looks for companies that are using AI to improve diagnostic accuracy, personalize treatment, streamline clinical workflows, and speed research. In this article, we present three stocks from a screener that illustrate how this theme is playing out in today’s public markets.

GeneDx Holdings (WGS)

overview: GeneDx Holdings is a genomics company offering whole exome and whole genome sequencing. By using AI to interpret complex genetic data, doctors can diagnose rare diseases, assess genetic risk, and support cancer testing, with a particular focus on pediatric patients.

operation: GeneDx generates approximately US$437.5 million in revenue and a segment adjustment of US$5.2 million from its Gene Dx segment, with all reported revenues of approximately US$442.7 million coming from the United States.

Market capitalization: 1.2 billion USD

For investors focused on AI in healthcare, GeneDx sits at the intersection of powerful software and high-value clinical decision-making, using a proprietary AI platform and growing rare disease datasets to interpret exome and genomic tests at scale. The company aims to return to profitability in 2026 and has already seen a significant increase in exome and genome volumes. At the same time, recent reductions in earnings guidance, impairments from the Fabric Genomics acquisition, and reliance on riskier funding highlight execution and financing pressures. Analysts see significant upside potential if growth and margin expectations are met, but recent volatility and insider selling suggest sentiment has yet to calm down, so a closer look at the full theory could be important now.

GeneDx’s rare disease dataset and AI engine could be the real story, but the funding pressures are just the headlines. Before your emotions turn around again, read about 2 important rewards and 2 important warning signs (1 is major!).

Insmed (INSM)

overview: Insmed develops and markets treatments for serious and rare pulmonary and neuromuscular diseases, combining approved products like ARIKAYCE with a late-stage pipeline that includes brensocatib for bronchiectasis, treprostinil palmityl for pulmonary hypertension, and early genetic and protein engineering programs for conditions such as Duchenne muscular dystrophy and amyotrophic lateral sclerosis.

Market capitalization: $29.6 billion

Insmed sits at the intersection of high unmet medical need and AI-powered drug development, combining ARIKAYCE-approved products with late-stage programs such as brensocatib and treprostinil palmityl. Management expects these programs to support the company’s path to positive cash flow by 2027 without new capital. Analyst comments and recent index inclusions indicate confidence in long-term potential, but investors still need to weigh historical losses, rising valuation metrics, and dependence on external funding. For those following AI in healthcare, a key consideration is how these clinical, regulatory, and financing elements come together in the medium term and what that means for risk and reward.

Insmed’s increased attention and late-stage progress in the pipeline may be masking important details of its risk-reward profile. So read on for 3 major rewards and 1 important warning sign.

Lantheus Holdings (LNTH)

overview: Combining long-standing radiopharmaceutical brands with new AI-enabled tools such as aPROMISE and PYLARIFY AI, Lantheus Holdings develops and markets diagnostic and therapeutic imaging products used by physicians around the world to detect and manage heart disease, cancer, and neurological diseases.

Market capitalization: $5.6 billion

Lantheus is at the center of AI-driven medical imaging, with products such as PYLARIFY AI and Neuraceq tied to large markets such as prostate cancer and Alzheimer’s disease, and a pipeline including MK-6240 and PNT2003 that could expand its reach in neurological and tumor imaging. Revenues have grown significantly and margins have improved over the past five years. The stock trades at a P/E below the industry average, even as analysts have raised their targets on the back of TruVu, PNT2003 and other late-stage assets. The problem is the high dependence on PYLARIFY, price pressure, redemption risk, and a capital structure built solely on risky borrowings. The combination of growth potential and concentration risk is something investors often overlook at first glance.

Lantheus’ earnings power and below-industry-average P/E suggest a story that the market may not be fully pricing in, especially with TruVu and PNT2003 on the horizon, so read on for 4 important payoffs and 1 important warning sign.

The three stocks in this article are just a starting point. The complete Transformative AI Healthcare Stocks screening feature flags 32 more companies with similarly compelling narratives that have not yet been seen in the Transformative Artificial Intelligence (AI) Healthcare Stocks screening feature.

Take control of your investment journey

If GeneDx Holdings or one of these companies has caught your attention, register for free on Simply Wall St and add your company to your watchlist to monitor stock prices compared to fair value and track any new developments. Once migrated, manage your holdings with a portfolio command center that filters out the noise and delivers only the most important and actionable updates. Our community allows you to filter the best ideas from thousands of investor perspectives throughout your journey. Discover hidden catalysts and risks early to accelerate decision-making and stay ahead of the market.

Looking for a fresh alternative before you leave?

Markets move quickly, and the next breakout list often goes unnoticed for now. Look at fresh ideas before you get carried away and consider acting before the situation changes.

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.